Mazdutide 5mg

Description

Strength: 5mg
CAS: 2259884-03-0
Chemical Formula: C₂₁₀H₃₂₂N₄₆O₆₇
Molecular weight: 4563.06 g/mol
Peptide Sequence: His-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-Lys-{AEEA-AEEA-γGlu-Nonadecanoic acid}-Glu-Phe-Val-Glu-Trp-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-NH2
Synonyms: IBI-362 (or IBI362) LY-3305677 (or LY3305677)
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

Mazdutide (5mg) is a research-grade 33-amino-acid peptide supplied as a sterile, lyophilized powder in a sealed vial to support stability, purity, and reproducibility in laboratory use. It is classified as a dual GLP-1 and glucagon receptor agonist, a design that has generated significant interest in metabolic research focused on coordinated regulation of glucose handling, lipid metabolism, and energy expenditure.

While not FDA-approved in the United States, mazdutide has received regulatory approval from China’s National Medical Products Administration (NMPA):

• June 2025: Approved for chronic weight management in adults with overweight or obesity
• September 2025: Approved for glycemic control in adults with type 2 diabetes

In jurisdictions where approval has not been granted, the compound remains a valuable research tool for laboratories investigating mechanisms of metabolic disease and next-generation incretin-based strategies. Researchers who buy mazdutide peptide typically do so for controlled, non-clinical experimental studies.

Mazdutide is supplied as a single-component peptide formulation intended for precise experimental application, with structural and analytical specifications aligned to those used in advanced research and clinical development programs.

• Single-Peptide Composition: Contains 5 mg of purified mazdutide per vial
  (molecular formula: C₂₀₇H₃₁₇N₄₅O₆₅)
• High Purity & Stability: Lyophilized presentation supports molecular integrity and long-term storage
• Research-Ready Format: Sterile, sealed vial designed for laboratory reconstitution and handling
• Primary Research Focus: Metabolic regulation, energy expenditure, glucose balance, and receptor signaling
• Advanced Research Evaluation: Studied in preclinical and phase 2/3 research settings (obesity and type 2 diabetes models)
• Regulatory Status: For laboratory research use only outside approved jurisdictions
• Supply & Documentation: Institutions that order mazdutide peptide typically require lot-specific analytical verification

Mazdutide is investigated as a dual GLP-1 and glucagon receptor agonist, a mechanism that differentiates it from single-pathway incretin peptides. In experimental systems, concurrent activation of these receptors has been associated with coordinated effects on glucose regulation, lipid metabolism, appetite signaling, and overall energy homeostasis.

Research models examine how this dual-receptor profile influences insulin sensitivity, metabolic rate, and energy expenditure. These properties make mazdutide a subject of interest in laboratory studies focused on obesity, diabetes, and broader metabolic disease mechanisms. All findings outside approved clinical use remain limited to experimental and non-clinical research contexts.

• Preclinical studies: 50–200 μg/kg administered subcutaneously
• Early clinical research: 4–6 mg once weekly subcutaneously
• Experimental dosing: Tailored to study endpoints, species, and duration

Reported research observations include:

• Changes in body weight and food-intake patterns
• Alterations in glucose and lipid metabolism markers
• Modulation of energy-expenditure–related pathways

All dosing outside approved jurisdictions should be conducted strictly in accordance with regulated research protocols.

Maintaining appropriate storage and handling conditions is essential for preserving peptide stability and ensuring reliable research outcomes.

• Lyophilized Storage: Store at 2–8 °C, protected from light and moisture, prior to reconstitution
• After Reconstitution: Refrigerate and use within 14 days to minimize degradation
• Handling Precautions: Avoid repeated freeze–thaw cycles to preserve peptide integrity

Clinical Safety Status

Phase 3 clinical safety evaluation has been completed with published results (Nature, 2025). These trials reported:

• No serious adverse events (SAEs) in the mazdutide treatment groups
• A favorable overall safety and tolerability profile
• Adverse events were predominantly gastrointestinal, consistent with the GLP-1 agonist class

For research use outside approved jurisdictions, all studies should be conducted in appropriately authorized laboratory environments.

References

https://pmc.ncbi.nlm.nih.gov/articles/PMC9561728/

https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00235-X/fulltext

https://pubmed.ncbi.nlm.nih.gov/34430840/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12704034/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.